Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CDT

Conduit Pharmaceuticals Inc

Apr 26 • 04:00PM ET

3.17

Dollar change +0.07
Percentage change 2.26	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.04	Insider Own	86.00%	Shs Outstand	73.83M	Perf Week	1.60%
Market Cap	234.04M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	10.34M	Perf Month	-11.20%
Income	3.54M	PEG	-	EPS next Q	-	Inst Own	2.53%	Short Float	0.40%	Perf Quarter	14.03%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	1.77%	Short Ratio	1.26	Perf Half Y	136.57%
Book/sh	-0.01	P/B	-	EPS next Y	-	ROA	4.89%	Short Interest	0.04M	Perf Year	-69.23%
Cash/sh	0.06	P/C	55.33	EPS next 5Y	-	ROE	5.37%	52W Range	0.95 - 25.00	Perf YTD	-30.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-87.32%	Beta	2.49
Dividend TTM	-	Quick Ratio	3.18	Sales past 5Y	0.00%	Gross Margin	-	52W Low	233.68%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	3.18	EPS Y/Y TTM	38.53%	Oper. Margin	0.00%	RSI (14)	49.84	Volatility	3.61% 7.91%
Employees	7	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-146.93%	Payout	-	Rel Volume	0.17	Prev Close	3.10
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	32.55K	Price	3.17
SMA20	-1.35%	SMA50	1.44%	SMA200	-40.08%	Trades		Volume	5,587	Change	2.26%

Mar-19-24 10:57AM	Conduit Pharmaceuticals Adds Key Leadership Positions (Exec Edge)
07:00AM	Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer (GlobeNewswire)
Mar-11-24 02:26PM	Conduit Pharmaceuticals Opens New Laboratory in UK (Exec Edge) +32.37%
07:00AM	Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences Hub (GlobeNewswire)
Jan-31-24 08:30AM	Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -7.42%
08:30AM	Loading…
Nov-02-23 08:30AM	Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference (GlobeNewswire)
Oct-30-23 08:39AM	Why Is Conduit Pharmaceuticals (CDT) Stock Up 66% Today? (InvestorPlace) +49.52%
Oct-11-23 08:30AM	Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656 (GlobeNewswire) -12.00%
Oct-06-23 09:29AM	Conduit Pharma CEO Tapolczay on Biopharma Differentiation, Pipeline (Exec Edge) -13.83%
08:30AM	Presidio Property Trust Announces Closing of Merger of Its Sponsored SPAC Murphy Canyon Acquisition Corp Now Trading as Conduit Pharmaceuticals (Nasdaq: CDT and CDTTW) (GlobeNewswire)
Sep-22-23 09:01AM	Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination (GlobeNewswire)
Sep-20-23 05:40PM	Murphy Canyon Acquisition Corp. Announces Stockholder Approval of the Proposed Combination with Conduit Pharmaceuticals Limited (ACCESSWIRE) -8.94%
Sep-13-23 08:30AM	Presidio Property Trust, Inc. Announces Establishment of a Special Committee of the Board and Exploration of Strategic Alternatives (GlobeNewswire)
Sep-07-23 04:30PM	Murphy Canyon Acquisition Corp. Announces Postponement of Its Special Meeting of Stockholders for Approving Its Initial Business Combination With Conduit (ACCESSWIRE)
Aug-31-23 04:05PM	Murphy Canyon Acquisition Corp. Announces Postponement of its Special Meeting of Stockholders for Approving its Initial Business Combination with Conduit (ACCESSWIRE)
08:30AM	Loading…
Aug-16-23 08:30AM	SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Murphy Canyon Acquisition Corp. with Conduit Pharmaceuticals Limited (ACCESSWIRE)

Conduit Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of clinical assets to address the unmet medical needs of patients, through exclusive relationships. Its medical needs in the areas of autoimmune disease and idiopathic male infertility. The company is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heilbron Jack Kendrick	Former CEO,director&10% owner	Sep 22 '23	Option Exercise	0.00	4,060,250	0	4,060,250	Sep 26 05:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CDT

Conduit Pharmaceuticals Inc

Upgrade your FINVIZ experience